Following the FDA, EMA also Grants an Orphan Drug Designation of SN Bioscience’s Nano Anti-Cancer Drug ‘SNB-101’ for Small Cell Lung Cancer.

SEOUL, South Korea, May 31, 2024 /PRNewswire/ — SN Bioscience Co., Ltd. (CEO Park Young-hwan) announced on May 24 that European Medicines Agency(EMA) had granted an orphan drug designation for small cell lung cancer(SCLC), a rare disease, for SNB-101 (API: SN-38) which is a new polymer…